Abstract: A novel mammalian cytokine, IL-11, and processes for producing it are disclosed. IL-11 may be used in pharmaceutical preparations for stimulating and/or enhancing cells involved in the immune response and cells involved in the proper functioning of the hematopoietic system.
Type:
Grant
Filed:
March 10, 1997
Date of Patent:
December 29, 1998
Assignee:
Genetics Institute, Inc.
Inventors:
Yu-Chung Yang, Frances K. Bennett, Stephan R. Paul
Abstract: Purified bone morphogenetic protein (BMP)-6 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and/or cartilage defects and in wound healing and related tissue repair.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
December 15, 1998
Assignee:
Genetics Institute, Inc.
Inventors:
John M. Wozney, Elizabeth A. Wang, Vicki A. Rosen, Anthony J. Celeste
Abstract: Purified chordin proteins and processes for producing them are disclosed. DNA molecules encoding the chordin proteins are also disclosed. The proteins may be used in the treatment of bone, cartilage, other connective tissue defects and disorders, including tendon, ligament and meniscus, in wound healing and related tissue repair, as well as for treatment of disorders and defects to tissues which include epidermis, nerve, muscle, including cardiac muscle, and other tissues and wounds, and organs such as liver, brain, lung, cardiac, pancreas and kidney tissue. The proteins may also be useful for the induction inhibition of growth and/or differentiation of undifferentiated embryonic and stem cells. The proteins may be complexed with other proteins, particularly members of the transforming growth factor-beta superfamily of proteins.
Type:
Grant
Filed:
November 14, 1996
Date of Patent:
December 8, 1998
Assignee:
Genetics Institute, Inc.
Inventors:
Edward R. LaVallie, Lisa A. Racie, Edward M. DeRobertis
Abstract: Compositions of proteins with chondrocyte and cartilaginous tissue inducing activity, as well as method of using those compositions, are disclosed. The compositions comprise one or more proteins of the transforming growth factor-.beta. (TGF-.beta.) superfamily of proteins, particularly bone morphogenetic proteins (BMPs), in combination with parathyroid hormone related polypeptide (PTHrP) or an equivalent PTH-like polypeptide. The compositions and methods are useful in the treatment of osteoarthritis, cartilage defects and in related tissue repair.
Abstract: Thrombolytic proteins are disclosed which have tissue plasminogen-type activity. The proteins are characterized by modification within the 94 amino acid N-terminus, and/or at Arg-275, and/or at one or more of the N-linked glycosylation sites. Methods for making these proteins are disclosed as are therapeutic compositions containing same.
Abstract: Cell culture media are provided containing high L-cystine concentration and low L-glutamic acid concentration. The media are useful for recombinant production of proteins using mammalian cell cultures.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
November 3, 1998
Assignee:
Genetics Institute, Inc.
Inventors:
Denis Drapeau, S. Robert Adamson, Yen-Tung Luan, Paul Thoday
Abstract: DNA molecules encoding mutant forms of bone morphogenetic proteins (BMP) are disclosed. The mutant forms of BMP can be produced bacterially and refolded to produce biologically active homodimers or heterodimers of BMP. A method of making such mutant BMPs is also disclosed.
Abstract: Methods and devices are disclosed for inducing growth of neural cells, and repairing neural defects in a mammal. The method comprises administering to said mammal at the site of neural defect, damage or depletion, an effective amount of a bone morphogenetic protein, either in admixture with a pharmaceutically acceptable vehicle, or adsorbed to a suitable matrix. The device comprises bone morphogenetic protein, optionally in combination with other factors, adsorbed on a suitable matrix and contained within an artificial nerve replacement vessel.
Type:
Grant
Filed:
May 5, 1995
Date of Patent:
May 26, 1998
Assignee:
Genetics Institute, Inc.
Inventors:
Elizabeth A. Wang, Josephine S. D'Alessandro, Dean M. Toriumi
Abstract: DNA molecules encoding mutant forms of bone morphogenetic proteins (BMP) are disclosed. The mutant forms of BMP can be produced bacterially and refolded to produce biologically active homodimers or heterodimers of BMP. A method of making such mutant BMPs is also disclosed.
Abstract: Purified BMP-15-related proteins and processes for producing them are disclosed. DNA molecules encoding the BMP-15-related proteins are also disclosed. The proteins may be used in the treatment of bone and cartilage and/or other connective tissue defects and in wound healing and related tissue repair.
Type:
Grant
Filed:
February 11, 1997
Date of Patent:
March 17, 1998
Assignees:
Genetics Institute, Inc., Vanderbilt University
Inventors:
Anthony J. Celeste, Jennifer L. Dube, Karen M. Lyons, Brigid Hogan
Abstract: Purified Bone Morphogenetic Protein-10 (BMP-10) proteins and processes for producing them are disclosed. DNA molecules encoding the BMP-10 proteins are also disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.
Abstract: The present invention relates to methods for the induction of tendon/ligament-like tissue formation, wound healing and ligament and other tissue repair, using a composition comprising BMP-12, BMP-13 or MP-52, or combinations of the above.
Type:
Grant
Filed:
December 22, 1994
Date of Patent:
August 19, 1997
Assignees:
Genetics Institute, Inc., President and Fellows of Harvard College
Inventors:
Anthony J. Celeste, John M. Wozney, Vicki A. Rosen, Neil M. Wolfman, Gerald H. Thomsen, Douglas A. Melton
Abstract: Purified Bone Morphogenetic Protein-11 proteins and processes for producing them are disclosed. Recombinant DNA molecules encoding the BMP-11 proteins are also disclosed. The proteins may be useful in regulating follicle stimulating hormone, such as for contraception, and for the induction of bone, cartilage and/or other connective tissue.
Abstract: Purified Bone Morphogenetic Protein-10 proteins and processes for producing them are disclosed. Recombinant DNA molecules encoding the BMP-10 proteins are also disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.
Abstract: Purified BMP-15-related proteins and processes for producing them are disclosed. DNA molecules encoding the BMP-15-related proteins are also disclosed. The proteins may be used in the treatment of bone and cartilage and/or other connective tissue defects and in wound healing and related tissue repair.
Type:
Grant
Filed:
May 18, 1995
Date of Patent:
June 3, 1997
Assignees:
Genetics Institute, Inc., Vanderbilt University
Inventors:
Anthony J. Celeste, Jennifer L. Dube, Karen M. Lyons, Brigid Hogan
Abstract: A composition comprising a pharmaceutically acceptable admixture of an osteogenic protein; a polymer matrix component selected from the group consisting of poly(lactic acid), poly(glycolic acid), and copolymers of lactic acid and glycolic acid; and an osteogenic protein-sequestering material.
Type:
Grant
Filed:
June 29, 1993
Date of Patent:
January 28, 1997
Assignee:
Genetics Institute, Inc.
Inventors:
Eyal Ron, Thomas J. Turek, Benjamin S. Isaacs, Himakshi Patel, Richard A. Kenley
Abstract: Methods are provided for the diagnosis and treatment of patients with increased risk of gestational hypertension or preeclampsia. The methods involve measuring serum M-CSF levels, and administration of M-CSF.
Type:
Grant
Filed:
March 23, 1995
Date of Patent:
December 3, 1996
Assignees:
Genetics Institute, Inc., Virginia Polytechnic Institute and State University
Abstract: A novel family of primate CSF-1-like polypeptides is provided via recombinant techniques, including compositions and methods for their production and use.
Abstract: Methods are provided for the diagnosis and treatment of patients with increased risk of gestational hypertension or preeclampsia. The methods involve measuring serum M-CSF levels, and administration of M-CSF.
Type:
Grant
Filed:
March 10, 1994
Date of Patent:
August 6, 1996
Assignees:
Genetics Institute, Inc., Virginia Polytechnic Institute and State Univ.